Baseline patient and disease characteristics
| Baseline characteristic, MEAN (SD) . | CANTOS (N = 10 061) . | Proteomic analysis set (n = 4595) . | Proteogenomic analysis set (n = 3458) . | No CH (n = 3154∗) . | CH (n = 304∗) . | CH without baseline anemia (n = 250†) . | CH with baseline anemia (n = 54∗) . |
|---|---|---|---|---|---|---|---|
| Age, y | 61.1 (10.04) | 61.95 (9.71) | 61.98 (9.67) | 61.56 (9.6) | 66.34 (9.27) | 65.49 (8.99) | 70.26 (9.65) |
| Female, n (%) | 2587 (25.7) | 1168 (25.4) | 858 (24.8) | 776 (24.6) | 82 (27.0) | 68 (27.2) | 14 (25.9) |
| BMI, kg/m2 | 30.64 (5.95) | 31.28 (6.05) | 31.2 (5.88) | 31.37 (5.91) | 29.48 (5.3) | 29.55 (4.88) | 29.16 (6.97) |
| hsCRP, mg/L | 6.62 (12.45) | 6.65 (15.7) | 6.54 (17.46) | 6.59 (18.21) | 6.02 (5.33) | 5.7 (5.14) | 7.55 (5.97) |
| Hemoglobin level, g/L | 141.91 (14.98) | 142.45 (14.71) | 142.9 (14.34) | 143.1 (14.26) | 140.83 (14.97) | 145.43 (11.91) | 119.52 (7.29) |
| Type 2 diabetes mellitus, n (%) | 4029 (40) | 1905 (41) | 1404 (41) | 1286 (41) | 118 (39) | 98 (39) | 20 (37) |
| Hypertension, n (%) | 8008 (80) | 3729 (81) | 2789 (81) | 2529 (80) | 260 (86) | 214 (86) | 46 (85) |
| Heart failure, n (%) | 2173 (22) | 915 (20) | 683 (20) | 600 (19) | 83 (27) | 64 (26) | 19 (35) |
| Anemia, n (%)† | 1316 (13.1) | 570 (12.4) | 399 (11.5) | 345 (10.9) | 54 (17.8) | 0 (0) | 54 (100) |
| IL-6, ng/mL | 4.07 (6.30) | 4.07 (6.37) | 4.02 (6.36) | 4 (6.41) | 4.14 (5.73) | 3.64 (3.85) | 6.38 (10.43) |
| IL-18, ng/mL | 287.35 (139.46) | 285.28 (138.59) | 286.49 (139.64) | 287.27 (141.23) | 278.18 (121.41) | 283.1 (120.9) | 256.1 (122.38) |
| Hepcidin, log2RFU | N/A | 13.92 (1.27) | 13.92 (1.24) | 13.94 (1.21) | 13.72 (1.47) | 13.82 (1.28) | 13.26 (2.11) |
| Platelet count, g/L | 232.44 (68.12) | 229.97 (68.18) | 232.42 (67.15) | 232.74 (66.74) | 229.18 (71.25) | 231.71 (71.77) | 217.48 (68.23) |
| IL-1 RA, ng/mL | 590.58 (477.5) | 591.48 (484.89) | 593.52 (477.77) | 600.53 (489.83) | 519.74 (316.19) | 531.22 (327.13) | 467.58 (256.94) |
| TNFα, ng/mL | 2.55 (6.41) | 2.48 (6.19) | 2.5 (6.77) | 2.46 (6.79) | 2.89 (6.46) | 2.98 (7.12) | 2.48 (1.3) |
| IL1β, log2RFU | N/A | 11.61 (0.48) | 11.6 (0.46) | 11.6 (0.45) | 11.61 (0.53) | 11.61 (0.5) | 11.6 (0.69) |
| Treatment, n (%) | |||||||
| Placebo | 3344 (33) | 1530 (33) | 1144 (33) | 1047 (33) | 97 (32) | 82 (33) | 15 (28) |
| 50-mg canakinumab | 2170 (22) | 998 (22) | 762 (22) | 692 (22) | 70 (23) | 58 (23) | 12 (22) |
| 150-mg canakinumab | 2284 (23) | 1062 (23) | 814 (24) | 743 (24) | 71 (23) | 58 (23) | 13 (24) |
| 300-mg canakinumab | 2263 (22) | 1005 (22) | 738 (21) | 672 (21) | 66 (22) | 52 (21) | 14 (26) |
| Baseline characteristic, MEAN (SD) . | CANTOS (N = 10 061) . | Proteomic analysis set (n = 4595) . | Proteogenomic analysis set (n = 3458) . | No CH (n = 3154∗) . | CH (n = 304∗) . | CH without baseline anemia (n = 250†) . | CH with baseline anemia (n = 54∗) . |
|---|---|---|---|---|---|---|---|
| Age, y | 61.1 (10.04) | 61.95 (9.71) | 61.98 (9.67) | 61.56 (9.6) | 66.34 (9.27) | 65.49 (8.99) | 70.26 (9.65) |
| Female, n (%) | 2587 (25.7) | 1168 (25.4) | 858 (24.8) | 776 (24.6) | 82 (27.0) | 68 (27.2) | 14 (25.9) |
| BMI, kg/m2 | 30.64 (5.95) | 31.28 (6.05) | 31.2 (5.88) | 31.37 (5.91) | 29.48 (5.3) | 29.55 (4.88) | 29.16 (6.97) |
| hsCRP, mg/L | 6.62 (12.45) | 6.65 (15.7) | 6.54 (17.46) | 6.59 (18.21) | 6.02 (5.33) | 5.7 (5.14) | 7.55 (5.97) |
| Hemoglobin level, g/L | 141.91 (14.98) | 142.45 (14.71) | 142.9 (14.34) | 143.1 (14.26) | 140.83 (14.97) | 145.43 (11.91) | 119.52 (7.29) |
| Type 2 diabetes mellitus, n (%) | 4029 (40) | 1905 (41) | 1404 (41) | 1286 (41) | 118 (39) | 98 (39) | 20 (37) |
| Hypertension, n (%) | 8008 (80) | 3729 (81) | 2789 (81) | 2529 (80) | 260 (86) | 214 (86) | 46 (85) |
| Heart failure, n (%) | 2173 (22) | 915 (20) | 683 (20) | 600 (19) | 83 (27) | 64 (26) | 19 (35) |
| Anemia, n (%)† | 1316 (13.1) | 570 (12.4) | 399 (11.5) | 345 (10.9) | 54 (17.8) | 0 (0) | 54 (100) |
| IL-6, ng/mL | 4.07 (6.30) | 4.07 (6.37) | 4.02 (6.36) | 4 (6.41) | 4.14 (5.73) | 3.64 (3.85) | 6.38 (10.43) |
| IL-18, ng/mL | 287.35 (139.46) | 285.28 (138.59) | 286.49 (139.64) | 287.27 (141.23) | 278.18 (121.41) | 283.1 (120.9) | 256.1 (122.38) |
| Hepcidin, log2RFU | N/A | 13.92 (1.27) | 13.92 (1.24) | 13.94 (1.21) | 13.72 (1.47) | 13.82 (1.28) | 13.26 (2.11) |
| Platelet count, g/L | 232.44 (68.12) | 229.97 (68.18) | 232.42 (67.15) | 232.74 (66.74) | 229.18 (71.25) | 231.71 (71.77) | 217.48 (68.23) |
| IL-1 RA, ng/mL | 590.58 (477.5) | 591.48 (484.89) | 593.52 (477.77) | 600.53 (489.83) | 519.74 (316.19) | 531.22 (327.13) | 467.58 (256.94) |
| TNFα, ng/mL | 2.55 (6.41) | 2.48 (6.19) | 2.5 (6.77) | 2.46 (6.79) | 2.89 (6.46) | 2.98 (7.12) | 2.48 (1.3) |
| IL1β, log2RFU | N/A | 11.61 (0.48) | 11.6 (0.46) | 11.6 (0.45) | 11.61 (0.53) | 11.61 (0.5) | 11.6 (0.69) |
| Treatment, n (%) | |||||||
| Placebo | 3344 (33) | 1530 (33) | 1144 (33) | 1047 (33) | 97 (32) | 82 (33) | 15 (28) |
| 50-mg canakinumab | 2170 (22) | 998 (22) | 762 (22) | 692 (22) | 70 (23) | 58 (23) | 12 (22) |
| 150-mg canakinumab | 2284 (23) | 1062 (23) | 814 (24) | 743 (24) | 71 (23) | 58 (23) | 13 (24) |
| 300-mg canakinumab | 2263 (22) | 1005 (22) | 738 (21) | 672 (21) | 66 (22) | 52 (21) | 14 (26) |
BMI, body mass index; Q, quartile; RA, receptor agonist; RFU, relative fluorescent units; SD, standard deviation.
Number of patients with baseline proteomic and genomic data available. N = 3585, 338, or 59 for No CHIP, CHIP, or CHIP with baseline anemia with only genomic data, respectively.
Anemia was defined as baseline Hb <120 g/L for females or <130 g/L for males.